Zhi Hong, Brii Biosciences CEO
July 6, 2023 07:05 AM EDTUpdated July 7, 02:06 AM
Deals

Brii Bio­sciences snaps up VBI Vac­ci­nes' HBV pro­grams in ex­pand­ed deal, jump­ing in­to com­mer­cial mode

Amber Tong

Five years af­ter bag­ging Chi­na rights to VBI Vac­cines’ he­pati­tis B ther­a­py and team­ing up on its de­vel­op­ment, Brii Bio­sciences is go­ing for the whole …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times